Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 9 January 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk. 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonLiselotte Hyveled2 Reason for the notificationa)Position/statusMember of the Board of Directors.b)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN3424 Details of the transaction(s)a)Description of the financial instrument,type of instrument,Shares Identification codeNovo Nordisk B DK0062498333b)Nature of the transactionTransfer of sharesc)Price(s) and volume(s)     Price(s)Volume(s)  DKK 683.901,420 shares         d)Aggregated information Aggregated volumePrice 1,420 sharesDKK 971,138.00e)Date of the transaction2023-11-03f)Place of the transactionOutside a trading venue 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonMaha Kutay2 Reason for the notificationa)Position/statusClosely associated person to Kasim Kutay, member of the Board of Directors.b)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN3424 Details of the transaction(s)a)Description of the financial instrument,type of instrument,Shares Identification codeNovo Nordisk B DK0060534915b)Nature of the transactionPurchase of sharesc)Price(s) and volume(s)     Price(s)Volume(s)  DKK 1,098.6614 shares         d)Aggregated information Aggregated volumePrice 14 sharesDKK 15,381.20e)Date of the transaction2023-04-12f)Place of the transactionNasdaq Copenhagen 1 Details of the person discharging managerial responsibilities/person closely associated a)Name of the Board member/Executive/Associated PersonMaha Kutay2 Reason for the notificationa)Position/statusClosely associated person to Kasim Kutay, member of the Board of Directors.b)Initial notification/AmendmentInitial notification3 Details of the issuera)NameNovo Nordisk A/Sb)LEI549300DAQ1CVT6CXN3424 Details of the transaction(s)a)Description of the financial instrument,type of instrument,Shares Identification codeNovo Nordisk B DK0060534915b)Nature of the transactionPurchase of sharesc)Price(s) and volume(s)     Price(s)Volume(s)  DKK 1,370.443 shares         d)Aggregated information Aggregated volumePrice 3 sharesDKK 4,111.33e)Date of the transaction2023-09-12f)Place of the transactionNasdaq Copenhagen Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 [email protected] DeLuca (US)+1 609 580 [email protected]: Daniel Muusmann Bohsen+45 3075 2175 [email protected] Martin Wiborg Rode+45 3075 [email protected] Heiberg Landsted +45 3077 6915 [email protected] Joseph Root (US) +1 848 213 [email protected] Meyer +45 3079 6656 [email protected] Taylor Pitter +45 3075 8259 [email protected] Company announcement No 3 / 2024
Attachment

CA240109-Insider-trading